|
End-of-day quote
Shanghai S.E.
2026-11-04
|
5-day change | 1st Jan Change | ||
| 10.93 CNY | +1.02% |
|
+0.74% | -6.58% |
Company Valuation: GuiZhou SanLi Pharmaceutical Co.,Ltd
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 8,252 | 6,483 | 5,637 | 7,738 | 5,205 | 4,735 |
| Change | - | -21.44% | -13.05% | 37.27% | -32.74% | -9.02% |
| Enterprise Value (EV) 1 | 7,872 | 6,041 | 5,212 | 7,670 | 5,313 | 5,084 |
| Change | - | -23.26% | -13.73% | 47.17% | -30.74% | -4.3% |
| P/E | 84.4x | 42.6x | 28x | 26.6x | 19.4x | 106x |
| PBR | 8.4x | 6.29x | 4.55x | 5.24x | 3.45x | 3.28x |
| PEG | - | 0.8x | 0.9x | 0.6x | -3.44x | -1.3x |
| Capitalization / Revenue | 13.1x | 6.9x | 4.69x | 4.73x | 2.43x | 2.78x |
| EV / Revenue | 12.5x | 6.43x | 4.34x | 4.69x | 2.48x | 2.99x |
| EV / EBITDA | 69.7x | 37x | 23.7x | 25.3x | 13.2x | 19.6x |
| EV / EBIT | 75.1x | 39.8x | 25.5x | 28.7x | 16.2x | 27.3x |
| EV / FCF | -133x | 110x | 40.8x | -209x | 54.4x | -88.4x |
| FCF Yield | -0.75% | 0.91% | 2.45% | -0.48% | 1.84% | -1.13% |
| Dividend per Share 2 | 0.25 | - | 0.1 | 0.2 | 0.34 | 0.06 |
| Rate of return | 1.23% | - | 0.73% | 1.06% | 2.62% | 0.51% |
| EPS 2 | 0.24 | 0.37 | 0.49 | 0.71 | 0.67 | 0.11 |
| Distribution rate | 104% | - | 20.4% | 28.2% | 50.7% | 54.5% |
| Net sales 1 | 630.2 | 939 | 1,201 | 1,635 | 2,144 | 1,703 |
| EBITDA 1 | 113 | 163.1 | 220.2 | 303.2 | 402.3 | 258.8 |
| EBIT 1 | 104.9 | 151.9 | 204.6 | 267.2 | 328.3 | 186.1 |
| Net income 1 | 93.95 | 152.3 | 201.3 | 292.7 | 274 | 46.25 |
| Net Debt 1 | -380.1 | -442.2 | -425.1 | -67.86 | 107.7 | 348.7 |
| Reference price 2 | 20.26 | 15.78 | 13.72 | 18.88 | 13.00 | 11.70 |
| Nbr of stocks (in thousands) | 407,322 | 410,862 | 410,862 | 409,862 | 400,382 | 404,740 |
| Announcement Date | 4/28/21 | 4/21/22 | 4/14/23 | 4/26/24 | 4/22/25 | 4/26/26 |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 648M | |
| 41.24x | 13.94x | 30.97x | 0.48% | 1,255B | |
| 38.96x | 6.55x | 18.42x | 2.01% | 641B | |
| 36.79x | 8.37x | 17.26x | 2.42% | 505B | |
| 21.08x | 5.12x | 12.75x | 2.56% | 381B | |
| 95.75x | 5.88x | 25.02x | 2.35% | 357B | |
| 22.88x | 5.88x | 14.19x | 2.73% | 303B | |
| 24.26x | 4.85x | 13.68x | 1.8% | 286B | |
| 29.25x | 7.46x | 13.36x | 2.19% | 249B | |
| -40.09x | 7.32x | 45.96x | 1.97% | 208B | |
| Average | 30.01x | 7.26x | 21.29x | 2.06% | 418.59B | |
| Weighted average by Cap. | 35.93x | 8.73x | 22.53x | 1.73% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 603439 Stock
- Valuation GuiZhou SanLi Pharmaceutical Co.,Ltd
Select your edition
All financial news and data tailored to specific country editions
